LuxSmart: Evaluation of the Extended Depth of Focus After Bilateral Implantation of Hydrophobic IOLs

Sponsor
Gemini Eye Clinic (Industry)
Overall Status
Completed
CT.gov ID
NCT04523558
Collaborator
(none)
33
1
1
9.4
3.5

Study Details

Study Description

Brief Summary

This will be a prospective observational, ethics committee approved study where patients undergoing routine cataract surgery will have bilateral implantation of the intraocular lens (LuxSmart, Bausch & Lomb). The device under investigation is CE-mark approved and commercially available. The device under investigation and all study products, including the devices used for the study examinations, will be used within the intended use specifications from the manufacturer. In addition, no invasive or other burdening examinations will occur for the patient.

Investigator is accredited and experienced cataract surgeon and researchers who have been involved in similar studies in the past.

The device under investigation LuxSmart (Bausch & Lomb) is a hydrophobic, acrylic copolymer containing UV absorber intraocular lens (IOL). The IOLs will be implanted as part of the routine cataract surgery on patients suffering from cataract development.

In total 30 patients will be recruited for this first clinical experience and receive bilateral implantation of the LuxSmart. The maximum time between 1st and 2nd eye implantation is 30 days, some patients may receive bilateral implantation on the same day. However there will be a minimum of 1 week between the implantations in the first 10 patients.

Condition or Disease Intervention/Treatment Phase
  • Device: Implantation of LuxSmart hydrophobic IOLs (Bausch + Lomb) in both eyes
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
33 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of the Extended Depth of Focus After Bilateral Implantation of a Hydrophobic IOL With a New Optic Concept Based on a Combination of High Order Aberrations
Actual Study Start Date :
Jun 25, 2020
Actual Primary Completion Date :
Apr 1, 2021
Actual Study Completion Date :
Apr 8, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Bilateral implantation of LuxSmart hydrophobic IOL

Cataract surgery will be carried out using standard phacoemulsification technique with a 2.2 mm incision. Investigators will target a 5.5 mm diameter capsulorhexis to allow the optic to be fully overlapped by the anterior capsular rim. The intended target of the post-operative refraction will be emmetropia. The patient will be implanted with LuxSmart hydrophobic IOLs in both eyes and followed up for 6 months

Device: Implantation of LuxSmart hydrophobic IOLs (Bausch + Lomb) in both eyes
Extended depth of field intraocular lens made form hydrophobic material

Outcome Measures

Primary Outcome Measures

  1. Corrected Distance Visual Acuity [6 months]

    Measurement of distance visual acuity is measured with 5 letters modified Snellen charts placed at 6 m distance with corrective glasses for each eye separately

Secondary Outcome Measures

  1. Manifest refraction (sphere, cylinder, axis) [6 months]

    Standard refraction technique

  2. Monocular Uncorrected Distance Visual Acuity (UDVA) [6 months]

    Measurement of distance visual acuity is measured with 5 letter modified snellen charts placed at 6 m distance without corrective glasses for each eye separately

  3. Binocular Uncorrected Distance Visual Acuity (UDVA) [6 months]

    Measurement of distance visual acuity is measured with 5 letter modified snellen charts placed at 6 m distance without corrective glasses for both eyes together

  4. Monocular Corrected Distance Visual Acuity (CDVA) [6 months]

    Measurement of distance visual acuity is measured with 5 letter modified snellen charts placed at 6 m distance with corrective glasses for each eye separately

  5. Binocular Corrected Distance Visual Acuity (CDVA) [6 months]

    Measurement of distance visual acuity is measured with 5 letter modified snellen charts placed at 6 m distance with corrective glasses for both eyes together

  6. Monocular Uncorrected Intermediate Visual Acuity (UIVA) [6 months]

    Measurement performed using ETDRS chart at 66 cm and 80 cm distance for one eye

  7. Binocular Uncorrected Intermediate Visual Acuity (UIVA) [6 months]

    Measurement performed using ETDRS chart at 66 cm and 80 cm distance for both eyes

  8. Monocular Distance Corrected Intermediate Visual Acuity (DCIVA) [6 months]

    Measurement performed using ETDRS chart at 66 cm and 80 cm distance for one eye

  9. Binocular Distance Corrected Intermediate Visual Acuity (DCIVA) [6 months]

    Measurement performed using ETDRS chart at 66 cm and 80 cm distance for both eyes

  10. Monocular Defocus Curve [6 months]

    Standard defocus curve with -5.0 to +1.5 D range lenses

  11. Monocular Contrast Sensitivity under photopic and mesopic conditions [6 months]

    Measurement of contrast sensitivity at 2.5 m

  12. Change in the Catquest-9SF score [6 months]

    o assess if difficulties in daily life occur due to impaired sight. This questionnaire is 9-item Rasch-scaled instrument to assess subjective perception of visual impairment after surgery.

  13. Spectacle independence [6 months]

    The PRSIQ is a patient-reported measure assessing spectacle independence following cataract surgery. The analyses conducted provide evidence for the use of the PRSIQ total score as a measure of spectacle independence.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Cataractous eyes with no comorbidity;

  • Calculated IOL power is within the range of the study IOLs;

  • Male or female adults ages 50 years or older on the day of screening who have cataract(s) in one or both eyes;

  • Regular corneal astigmatism ≤1.5D (measured by an automatic keratometry) in one or both eyes;

  • Clear intraocular media other than cataract;

  • Dilated pupil size large enough to visualize IOL axis markings postoperatively

  • Availability, willingness, skills and cognitive awareness enough to comply with the follow-up/study procedures and study visits.

  • Subjects able to read, understand and provide written Informed Consent Form on the Ethics Committee approved Informed Consent Form and provide authorization as appropriate for local privacy regulations.

Exclusion Criteria:
  • Age of patient <50 years;

  • Regular corneal astigmatism >1.5D (measured by an automatic keratometry) in both eyes;

  • Irregular astigmatism;

  • Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal or optic disorders) that are predicted to cause future acuity losses to a level of 20/30 or worse;

  • Subjects with AMD suspicious eyes as determined by OCT examination;

  • Subjects who may be expected to require retinal laser treatment during the course of the study or at a greater risk of developing cystoid macular edema;

  • Previous intraocular or corneal surgery;

  • Traumatic cataract;

  • History or presence of macular edema;

  • Instability of keratometry or biometry measurements;

  • Advanced or decompensated glaucoma;

  • Significant dry eye;

Contacts and Locations

Locations

Site City State Country Postal Code
1 Gemini Eye Clinic Zlín Czechia 760 01

Sponsors and Collaborators

  • Gemini Eye Clinic

Investigators

  • Principal Investigator: Pavel Stodulka, Gemini Eye Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr. Pavel Stodulka, Chief Eye Surgeon, Gemini Eye Clinic
ClinicalTrials.gov Identifier:
NCT04523558
Other Study ID Numbers:
  • LuxSmart_2020
First Posted:
Aug 21, 2020
Last Update Posted:
Jun 28, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 28, 2021